Janowiak Lab

Welcome to the Janowiak lab web pages!

The Janowiak lab has two main focuses:

1. Antibiotic design and discovery against Streptococcus agalactiae (Group B Streptococcus, GBS)

2. Antibiotic discovery and biotherapeutics against multiple drug resistant bacteria 

A summary of each focus is described below:

Antibiotic design and discovery against Streptococcus agalactiae (Group B Streptococcus, GBS)

Group B Streptococcus (GBS) is a bacterium which normally resides in the healthy women’s vaginal microbiome but can become pathogenic, causing severe infections in newborns. Pregnant mothers are screened for GBS and given antibiotics during pregnancy to remove the bacterium prior to delivery, preventing the infection of the babies. However, many of the babies later develop many inflammation disorders such as asthma and life-threatening allergies, which are now being attributed to the babies not obtaining a healthy microbiome at birth. Based on our published results showing that glutathione synthesis contributes to GBS virulence in a mouse model of sepsis, we are currently designing, testing, and validating glutathione synthesis inhibitors as potential antibiotic targets against GBS. 

Antibiotic discovery and biotherapeutics against multiple drug resistant bacteria

ESKAPE pathogens are very hard to treat and include six opportunistic bacteria that exhibit multidrug resistance and virulence: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. Persistent use of antibiotics has provoked the emergence of multidrug resistant bacteria, which render even the most effective drugs ineffective. It is critical that new antibiotics and biotherapeutics are discovered to help treat infections caused by ESKAPE pathogens. We currently have two aims:

1) Test antibiotic activity of various natural products against ESKAPE pathogens to determine optimal concentrations of the active ingredient(s) to inhibit growth and/or kill the bacteria. Our lab performs preliminary & secondary screening assays, minimal inhibitory concentration (MIC) assays and minimal bactericidal concentration (MBC) assays of active ingredients of putative antibiotics and other natural products against ESKAPE pathogens. This aim is done in conjunction with the Institute for Drug and Biotherapeutic Innovation (IDBI) Microbe Screening Core along with active collaborations with the labs of John Tavis, Marv Meyers, and John Walker. 

2) Isolate, purify, and identify antibiotic-producing bacteria and antibiotic-producing fungi from various soil samples collected from the environment. This project is spearheaded by my course-based undergraduate research experience (CURE) course in Antibiotic Resistance and Antibiotic Discovery (BIOL 4420, taught each spring semester). Follow-up, confirmation, and quantification screens against all ESKAPE pathogens is performed in my research lab. Identification involves sequencing 16S genes and ITS regions for the bacteria and fungi, respectively. 

For more information about our research, please feel free to contact me at blythe.janowiakmulligan[at]slu.edu, or check out my ResearchGate, Academia.edu, Google Scholar, or LinkedIn pages.

Dr. Janowiak also is the director of the Institute for Drug and Biotherapeutic Innovation Summer Program for Undergraduate Research (IDBI-SPUR). Find out more information about that program here.

Thanks for visiting!

*Janowiak Lab Banner Image credit: former undergrad researcher, Katie Vaeth (see Almuni lab)

Last updated: January 20, 2026